FDA approvals are critical milestones for pharmaceutical companies, often leading to increased investor confidence and potential revenue growth from the newly approved drug. Given that TARPEYO is now approved, it is likely to contribute positively to Calliditas Therapeutics' financials and strategic positioning in the market, thus the stock is likely to see a short-term increase in value.